Attorney Docket No. 13183.0037



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on Tune 39, 2004.
Michael L. Culotta

Signature

Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter Rohnert

Filed: January 26, 2004 Serial No.: 10/764,676

For: Drug Preparation Comprising Alpha-Lipoic Acid, Ambroxol And/Or Inhibitors Of The Angiotensin-Converting Enzyme (ACE) And Its Use

For The Treatment Of Neurodegenerative Diseases

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicant wishes to make of record the following references under the provisions of 37 C.F.R. §1.97 (legible copies of the references are enclosed).

US 2002/0177558 A1
WO 02/096398 A2
WO 02/096414 A1
European Search Report
corresponding to 04001224.7-2107
Jablonka et al.

Kozhevnikova et al. Packer et al.

Ravati et al. Stoll et al.

Werner et al.

Please see attached form PTO/SB/08A for a listing of the references.

It is believed no fee is due with this *Information Disclosure* Statement. If a fee is due, please charge deposit account number 08-2442.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventor, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)).

Respectfully submitted,

y: John D. Lopinski, Reg. No. 50,846

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Date: June 29, 2004

BFLODOCS 939526v1 (K4XY01!.DOC)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	( ose as many sneed as nee			Examiner Name	
Sheet	1	of	2	Attorney Docket Number	13183.0037

) Approved for use thro	ough 05/31/2003,	OMB 0651-0031
Application Number	10/764,676	
Filing Date	January 26, 20	00015
First Named Inventor	Peter Rohnert	/
Art Unit	1615	JUL 0 2 2004
Examiner Name		
Attorney Docket Number	13183.0037	12

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines Where Relevant
Initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
		US-2002/0177558 A1	11-28-2002	Meyerhoff et al.	
		US-			i
		US-			

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines	
Examiner Initials* Cite No. 1 Country Code <sup>3</sup> Number Kind Code <sup>5</sup> (if known) Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	т <sup>6</sup>			
		WO 02/096398 A2	12-05-2002	Esparma GmbH et al.		
		WO 02/096414 A1	12-05-2002	Serumwerk Bernburg AG		
	<u> </u>					

Examiner	 Date	
Signature	Considered	

BFLODOCS: 939527 v1 (K4XZ01!.DOC)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

			Ditailinet I talle	
Sheet 2	of	2	Attorney Docket Number	131

Application Number 10/764,676

Filing Date January 26, 2004

First Named Inventor Peter Rohner Group Art Unit 1615

Examiner Name JUL 0 2 2004

Attorney Docket Number 13183.0037

		NON PATENT LITERATURE DOCUMENTS	6405 S.
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		European Search Report corresponding to 04001224.7-2107.	
		JABLONKA, STANISLAW, ANDRZEJ LEDWOZYW, WOJCIECH KADZIOLKA, ANDRZEJ JABLONKA, AND ANDRZEJ NESTOROWICZ, "The Influence Of Ambroxol On Peroxidative Processes In Lung And Plasma In Dogs After Pulmonectomy," <u>Archivum Veterinarium Polonicum</u> , 1992, Pages 57-66, Volume 32, Number 1-2.	
		KOZHEVNIKOVA, E.V. AND L.M. ADZHIENKO, "Neuroprotective Activity Of Angiotensin-Converting Enzyme Inhibitors In Cerebral Ischemia," <u>Bulletin Of Experimental Biology And Medicine</u> , 1999, Pages 1122-1124, Volume 11.	
		PACKER, LESTER, HANS J. TRITSCHLER, AND KLAUS WESSEL, "Neuroprotection By The Metabolic Antioxidant α-Lipoic Acid," Free Radical Biology & Medicine, 1997, Pages 359-378, Volume 22, Numbers 1/2.	
		RAVATI, ALEXANDER, VERA JUNKER, MARIA KOUKLEI, BARBARA AHLEMEYER, CARSTEN CULMSEE, AND JOSEF KRIEGLSTEIN, "Enalapril And Moexipril Protect From Free Radical-Induced Neuronal Damage In Vitro And Reduce Ischemic Brain Injury In Mice And Rats," <u>European Journal Of Pharmacology</u> , 1999, Pages 21-33, Volume 373.	
		STOLL, S., A. ROSTOCK, R. BARTSCH, E. KORN, A. MEICHELBÖCK, AND W.E. MÜLLER, "The Potent Free Radical Scavenger α-Lipoic Acid Improves Cognition In Rodents," <u>Annals New York Academy Of Sciences</u> , 1994, Pages 122-128.	
		WERNER, CHRISTIAN, WILLIAM E. HOFFMAN, EBERHARD KOCHS, SARA F. RABITO, AND DAVID J. MILETICH, "Captopril Improves Neurologic Outcome From Incomplete Cerebral Ischemia In Rats," <u>Stroke</u> , July 1991, Pages 910-914, Volume 22, Number 7.	
			!

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached. Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. BFLODOCS: 939527 vI (K4XZ01!.DOC)